Modality
Small Molecule
MOA
WRNi
Target
JAK1
Pathway
Neuroinflam
UCNarcolepsy
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
→ Jul 2026
Phase 2Current
NCT03802454
126 pts·Narcolepsy
2021-01→2026-07·Completed
126 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-194mo awayPh2 Data· Narcolepsy
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P2
Complet…
Catalysts
Ph2 Data
2026-07-19 · 4mo away
Narcolepsy
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03802454 | Phase 2 | Narcolepsy | Completed | 126 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |